Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI®▼ (teclistamab) in Combination with DARZALEX® (daratumumab) Subcutaneous (SC) Formulation and Lenalidomide in Relapsed or Refractory Multiple Myeloma
Initial Phase 1b study results show clinical activity with immune-based triplet therapy regimen1 BEERSE, Belgium,…
raddar to Become a Mass-Media Platform with National Scale and Local Precision
Dynabook Portégé Z40L-N: The No-Dongle Travel Companion Your Staff (And You!) Actually Need